Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I dose-escalation study of KP-483 in patients with solid tumors
jRCT2031220311Phase 1Completed
- Sponsor
- KAKEN PHARMACEUTICAL CO., LTD.
- Start
- Sep 2022
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KP-483 in Nonhematologic neoplasms, sponsored by KAKEN PHARMACEUTICAL CO., LTD. Primary endpoint: Dose limiting toxicity. Started Sep 2022; status: completed.
02
Drugs
KP-483
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031220311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220311.